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Inoculation ofan established endothelial ceUl line
from transgenic mouse hemangiomas (Py-4-1)
into histocompatible mice induced vascular tu-
morformation at the site of injection with 100%
frequency. Histological and hematological stud-
ies revealed that the mice developed hemangio-
mas with hematological changes similar to those
found in the Kasabach-Merritt syndrome in hu-
mans, including hemolytic anemia and thrombo-
cytopenicpurpura. Modifications in the redblood
ceUcount, hemoglobin concentration, hematocrit,
and platelet count were directly correlated with
the size of the hemangioma. Thus transgenic
endothelial ceU injection into histocompatible
mice provides an in vivo model system to study
the pathobiology of hemangiomas as weU as the
investigation of angiogenesis inhibitors. (Am J
Pathol 1994, 144:796-806)
Hemangiomas are angiomatous malformations/
growths characterized by a proliferation of vascular
endothelium. Hemangiomas occur in 10% of children
and are the most common nonmalignant tumors of
infancy.1 Approximately 75% of these lesions are rec-
ognized in the neonatal period. The majority of cap-
illary hemangiomas resolve spontaneously as the
children grow older.2 Developing or enlarging heman-
giomas may obstruct, compress, or destroy vital
structures and thereby cause disfigurement or seri-
ous disability. Occasionally, these lesions cause
thrombocytopenia, consumptive coagulopathy, and
microangiopathic hemolytic anemia.3 Such compli-
cations are characteristic of the Kasabach-Merritt
syndrome.3 This syndrome is usually seen in early
infancy but, it may occur in later childhood or adult-
hood.5'7 The majority of vascular neoplasms in the
Kasabach-Merritt syndrome occur at a single site on
the limbs and the trunk.7
Transgenic mice expressing the entire polyoma vi-
rus early region gene develop multifocal tumors of the
vascular endothelium.8 These tumors, defined as he-
mangiomas, appear in adult mice, usually at different
sites. In a previous report, we established a cell line,
Py-4-1, from hemangiomas occurring in these mice.9
Py-4-1 cells have retained vascular endothelial cell
properties such as cobblestone appearance at con-
fluence, contact inhibited growth, expression of von
Willebrand factor (vWF), active uptake of acetylated
low-density lipoprotein, and organization into
capillary-like structures when cultured on a basement
membrane-like matrix, Matrigel9 (and unpublished
data). Furthermore, Py-4-1 cells are tumorigenic in
nude mice and histocompatible mice.9
Here the pathological and hematological features
associated with the development of hemangioma
after injection of Py-4-1 cells in mice are described.
Two other murine models of induced vascular tumors
have been reported.10'11 In one model, syngeneic
mice transplanted with hemangioendotheliomas de-
veloped hemangiomas.10 However, the tumor was a
mixed cell population, so nonendothelial cells present
in the tumor may have contributed to tumor develop-
ment. In a second model, inoculation of a cell line
derived from ultraviolet-induced murine skin tumors
was shown to induced hemangiomatous tumors in
nude mice, but no hematological study was reported
along with tumor progression.11 In our model, we
show that injection of a pure population of cultured
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endothelial cells (Py-4-1) in histocompatible mice
caused a single hemangioma to develop at the site of
injection with 100% frequency. Furthermore, these
mice developed many of the features of the
Kasabach-Merritt syndrome,36 including thrombo-
cytopenia, anemia, and splenomegaly. This animal
model may serve to study the features and compli-




B6D2F1 mice were purchased from the Jackson
Laboratory, Bar Harbor, ME. Four- to 6-week-old fe-
males were used in the present study. The animal
facility is approved by the American Association for
Accreditation for Laboratory Animal Care and is un-
der the care of Dr. J. Pick. Py-4-1 is a hemangioma-
derived endothelial cell line isolated from a trans-
genic mouse carrying the polyoma virus early
region as described previously.9 Cells were main-
tained in Dulbecco's modified Eagle's me-
dium supplemented with newborn calf serum at
37 C in a humidified atmosphere of 10% CO2
in air. Cells have been continuously passaged
at confluence after treatment with trypsin-
ethylenediaminetetraacetic acid buffered solution for
over 100 passages.
Py-4-1 Cell Inoculation
Inoculation of 3 x 106 Py-4-1 cells in 100 p1
phosphate-buffered saline (PBS) was made through
a 25G 5/8 needle into the subcutaneous tissues of the
thigh of 40 B6D2F1 mice or in the peritoneal cavity of
five B6D2F1 mice. Fifteen control mice of the same
genetic background were injected with 100 pl PBS at
the same site. Mice were sacrificed by cervical dis-
location at the times indicated.
Histology
Tissue specimens from the site of inoculation and
various organs were fixed with Bouin's fixative, em-
bedded in paraffin, and sectioned on a microtome.
Specimens were stained with hematoxylin and eosin
and observed by light microscopy.
Immunohistochemical Analysis
Deparaffinized sections of tissue specimens fixed
with Bouin's fixative were pretreated with 3% H202 in
methanol for 10 minutes, washed in PBS and incu-
bated with 0.05% trypsin (Boehringer Mannheim, In-
dianapolis, IN) for 30 minutes at 37 C. Sections were
then blocked with Dulbecco's modified Eagle's me-
dium containing 10% (v/v) goat serum, 1% (w/v) bo-
vine serum albumin, 50 mmol/L Hepes (pH 7.2), and
incubated for 2 hours at 37 C with rabbit anti-human
vWF, 1:100 (Dakopatts, Carpinteria, CA) in PBS con-
taining 1% bovine serum albumin. Slides were then
washed twice with PBS, incubated with biotinylated
goat anti-rabbit immunoglobulin G (Zymed Labora-
tories Inc., San Francisco, CA) for 10 minutes at room
temperature. Sections were developed by treatment
with a Streptavidin-Biotin Amplified System
(Histostain-SP kit, Zymed Laboratories Inc., San Fran-
cisco, CA). Sections were then counterstained with
hematoxylin and mounted using standard proce-
dures.
Electron Microscopy
Ultra-thin sections were made according to standard
procedure. Briefly, tissue specimens were cut into
small pieces, fixed with 3% glutaraldehyde for 3 hours
at room temperature, postfixed in 1 % osmium tetraox-
ide, dehydrated, and embedded in Araldite-502. Ul-
trathin sections were cut at 70 nm, stained in 4%
aqueous uranyl acetate and 0.5% lead citrate, and
observed with a Zeiss 10A transmission electron mi-
croscope at a voltage of 80kV.
Blood Studies
Blood samples were obtained by heart puncture
and collected in vacutainer (Becton-Dickinson Va-
cutainer Systems, Rutherford, NJ). Hematocrits
were measured using nonheparinized micro-
hematocrit capillary tubes (Fisher Scientific, Pitts-
burgh, PA). Blood-filled capillary tubes were sealed
with a tube-end sealer, and spun for 3 minutes us-
ing an IEC MB centrifuge (International Equipment
Co., Boston, MA). Ratio were determined using a
micro capillary reader (International Equipment Co.,
Boston, MA). To measure the hemoglobin level,
blood samples were treated with ZAP-OGLOBIN II
as the lysing agent for red blood cells (Coulter Di-
agnostics, Hialeah, FL). Hemoglobin levels were
measured in the lysed samples using a Coulter He-
moglobinometer (American Scientific Products, Mc-
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Figure 1. vWt immuwiostaininzg of early stages of P1-4-1 hemangiomas. A and B: Inijection site 20 holurN after P -4-1 in-iocuilation. Note the aggre-
gates ofjplunip vWF-positive neoplastic cells (scale bar = 75 j and 50 p respectively). C and D: Hemanigionia oni day 3. The neoplastic endothelial
cells organized into lumen-conttainintg struIctures filled uwith erythrocytes (scale bar = 75 ). E: Hemangioma ont dal 6. Endothelial cells (arrous)
are seen in the muiiiscle tissuie suirrounlding the cystic cavity ( c) (scale bar = 150 1). F: Higher magntfication of( E). The neoplastic cellsfornm a loose
lumen filled uith erythrocytes (arrous) (scale bar = 75 X).
Gaw Park, IL). Red blood cell (RBC) counts were
determined using a Coulter Counter model ZBI
(Coulter Electronics Inc., Hialeah, FL). White blood
cell counts were determined manually using a Uno-
pette micro collection system (Becton-Dickinson).
Blood smears were obtained by drawing a drop of
blood across a slide and air-drying. For bone mar-
row smears, femurs were dissected and cut at one
edge. A drop of bone marrow was then deposited
on a slide and drawn across. Blood and bone mar-
row smears were then stained with Diff Quick Stain
Set, a modification of Wright-Giemsa stain (Baxter
Health Care Corp., McGaw Park, IL). Platelet counts
were performed manually using a Unopette micro
collection system (Becton-Dickinson). Reticulocyte
determination was performed manually with the
Unopette test 5821 procedure using new methylene
blue N as the stain (Becton Dickinson). Blood cell
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Figure 2. Histological study of the early stages of Py-4-1 bemangiomas. A: Histology on day 5. The tumor has masses of neoplastic cells without
recognizable spaceformationt (bottom), anld vascular spacesfilled with erythrocYtes (top) (scale bar = 150 P). B: Histology on dal 7. Spongifornm
stnrctures wvith vtarious sizes of cyIsts are seen. The cysts have thick walls composed of nieoplastic cells (scale bar = 300 p). C: Histology on daY 7.
Cells are seen in the cystic cavity, arranged in septumlike cords or aggregates (arrouws) (scale bar = 300 1)0. D: Histology oni day 7. Neoplastic cells
with prominenit nuclei and niuxmerouis mitotic figurres are seen (arrows) (scale bar = 75 p).
Results
General Description
Hemangiomas developed in the subcutaneous tissue
in 100% of the 40 mice injected with Py-4-1 cells,
whereas the 15 mice inoculated with PBS did not
show any abnormal features at the site of injection. In
Py-4-1-injected mice, tumor growth appeared as a
single mass at the site of injection. Hemangiomas de-
veloped rapidly, and typically, a bulky mass 1 cm or
more in diameter was palpable within 2 to 3 weeks
after injection. The tumors were partially encapsu-
lated and were composed of soft dark-red tissues that
exuded dark blood upon sectioning. Hemorrhage into
the tumor was a prominent gross feature. Metastases
were not found in any of the tumor-bearing mice. The
tumor-bearing animals died spontaneously 3 to 5
weeks after injection of the Py-4-1 cells. When Py-4-1
cells were injected intraperitoneally, multiple small tu-
mors of similar appearance resulted. The tumor nod-
ules involved the peritoneal surface but did not pen-
etrate deeply into the organs or spread outside the
peritoneal cavity. Animals of this group died sponta-
neously 1 to 2 weeks after inoculation. Hemangioma
development in subcutaneously injected mice was
further studied because hemangiomas appeared at a
single cutaneous site and thus are more likely to
mimic hemangioma formation in humans.
Histological Findings
Histological sections stained with hematoxylin and
eosin or immunostained for vWF, an endothelial cell
marker, were prepared from mice sacrificed at differ-
ent times after subcutaneous injection of Py-4-1 cells.
Py-4-1 cells were present in small aggregates at the
site of injection immediately after inoculation (Figure
1 A). The neoplastic cells had a plump appearance as
opposed to normal flat endothelial cells (Figure 11B).
Endothelial cells formed lumenlike structures contain-
ing erythrocyte-filled spaces as soon as 3 days after
injection (Figure 1, C and D).
On day 5 to day 7 after injection of Py-4-1 cells, the
tumor was composed of very immature endothelial
cells with extensive atypia. In some areas, masses of
endothelial cells occurred without recognizable
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Figure 3. Histological stucdy of the late stages oJ Py-4-1 hemangiomas. A: Histology at daY 15. Tick cyst walls composed of a mfultilayer of tlmor
cells arc seeu (scale bar = 75 p). B: Histology oni day 15. A nvall of nieoplastic cells separating three cystic cavzities filled with erythrocytes is shown
(scale bar = 75 i). C: Histology oui day 17. Caeities shou a large collectioni of blood anzdfibrin (F = fibin). Cyst walls are disnrpted in this arcea
anid shuni, tumnor cells (arrous) slurrolunded by blood cells (scale bar= 75 P). D: Histology oni day 17. Nutimerouis immaturefJ)rmis of erythrocytes
intcluidinzg reticulocytes are surrounded bi'fihrin deposits in the tlumor cality (top) (scalec bar = 3() y).
space formation (Figure 2A). In other places, endo-
thelial cells formed a spongiform structure composed
of various sizes of endothelial lined cysts (Figure 2B).
In some areas, tumor cells apparently proliferated into
the cystic cavity, producing septumlike cords or ag-
gregates that occasionally contained lumenlike
spaces (Figure 2C). The neoplastic endothelial cells
showed prominent nuclei and numerous mitotic fig-
ures (Figure 2D). In some areas, the tumor cells
seemed to invade the muscle tissue surrounding the
cystic cavities by infiltrating between the muscle
bundles (Figure 1, E and F). In the muscle, they
formed a lumen containing erythrocytes (Figure 1F).
Numerous erythrocytes and a few leukocytes seemed
to be trapped in the tumor cavities and between the
neoplastic cells.
On days 14 to 17 after injection of Py-4-1 cells, the
size of the hemangioma had reached approximately
1 cm in diameter, and it was composed of various
sizes of cysts. Walls of the cysts were thicker and
consisted of a multilayer of cells with giant nuclei (Fig-
ure 3, A and B). Tumor cavities contained a large col-
lection of blood cells including erythrocytes and a few
neutrophils. Occasionally, cyst walls were disrupted,
revealing endothelial cells surrounded by blood cells
(Figure 3C). A light pink color indicated deposits of
fibrin in the cavities (Figure 3C). Numerous immature
and abnormal forms of erythrocytes as well as reticu-
locytes were observed in the tumor cavities (Figure
3D). On day 21 after Py-4-1 cell injection, the septa-
tion between cystic cavities had often disappeared,
and the former cysts were coalesced into a single cyst
(data not shown). A large collection of blood with
many inflammatory cells was observed in the cavity.
Electron Microscopy Findings
The vascular tumors were examined by electron mi-
croscopy at day 5 after injection (Figure 4). The neo-
plastic endothelial cells lining vascular spaces were
very irregular (Figure 4A) and often had interdigita-
tions and irregular microvilli projecting into the blood
space (Figure 4B). The endothelial cells had a plump
appearance with signs of intracellular activity, such as
convoluted nuclear membranes, swollen mitochon-
dria, and rough endoplasmic reticulum (Figure 4, B
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Figure 4. Flectron mnicroscopy stlucdp oJ' Pp 4 1
hemanigioma on dap 5 (A to D), anld daY 21 (E
IEAr% A ..... .. . .............. , . ..r "anid F). A: Hemansgioma cavizty uito Itometn ()
filled nith egrthrocYtes. The nalls of the heinan-
giomna were a mnlntil/aVer oJ' toimoral enidothelial
cells ( 1, 700X ). B: Irregilar microv'illi oj' tCeO-
plastic endothelinim projected inito the luimien (L)
of' vascular space. Note the pluminp endo)thelial
ceil (EC) with sign of' initracellutlar actii'itp
(10. Ox ). C: Numerous platelets (arrow') were
present in the lumen (L). Neoplastic cells had a
mnltilalpered inregnliar basal laniiniia (Bil)
(5,OOOx ). D: Deposits ofcollagen fibers ( C) were
fortned ont the basal side of the cells (.3,200X).
E: At dapc 21, the vascular lining was poorl/p de-
limnited. Pl/ngs ofiYbrint fibers, platelet aggregates.
erpthrocptes, and cell debris uwere present in the
lIumeni (L) as well as itifiltratinig between the ti-
mor nalls composed of enidothelial cells (IC)
(.3,200X). F: Higher magnification of inaterial
fonniid in the lumnen of the poorl/ organizcvled tas-
cular space at day 21 (6,400X).
and C). They showed poorly developed intercellular
junctions and were frequently surrounded by a basal
lamina irregular in thickness (Figure 4, C and D). Inter-
stitial components such as collagen fibers were abun-
dant between the neoplastic cells of the thick walls of
the tumor (Figure 4D). Pericytes or smooth muscle
cells were not detected. Platelet aggregates and
erythrocytes were abundant in the lumen (Figure 4C).
At day 21 after injection, the lumina of the heman-
gioma cavities were poorly delimited (Figure 4E).
Abundant fibrin deposits, platelet aggregates, RBCs,
and cell debris were found in the lumen (Figure 4, E
and F). A striking feature was the extensive distortion
of erythrocytes (Figure 4, E and F).
Observation of Other Organs
There was no difference in size and histology of heart,
lungs, liver, adrenals, and kidneys (data not shown).
However, splenomegaly was a characteristic finding
in the mice with tumors (Figure 5A). The mean splenic
weight at day 21 was 0.5 g compared to 0.07 g in
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Days after injection
Figure 5. Spleen size analysis in tumor-bearing mice. A: Size com-
parison between a normal spleen (left) and the spleen of a mouse
uith a subcutaneous heman1gioma at 25 dayspostinjection (right). B:
Time course of the spleen uweight in tumor-bearing mice. Students
t-test compared to control. day 9, P < 0.001; daly 15, P < 0.01; day
21, P < 0.01.
amination of the spleen from mice with tumors
showed no abnormal features (data not shown).
Blood Analysis
As the hemangioma increased in size, the mice de-
veloped thrombocytopenia and anemia. Each of the
circulating blood parameters studied, RBC count, he-
moglobin concentration, hematocrit and platelet
count decreased as the tumor size increased (Figure
6). One to 3 days after injection of the Py-4-1 cells, the
mice had a significant decrease in RBC count (P <
0.01) (Figure 6A). Two weeks later, the tumor-bearing
mice showed a pronounced anemia with a RBC count
one-third of the normal count (P < 0.001) (Figure 6A).
At the terminal stage, the RBC count was as low as
1 million per pl in some mice. The hemoglobin level
decreased severely during the course of heman-
gioma development and correlated with the decrease
in RBCs (Figure 6B). The mean hematocrit value in the
tumor mice reduced significantly 14 to 17 days after
injection (P < 0.003) and was 18% compared to 30%
in controls (Figure 6C). As the tumor increased in size,
the anemia became more severe and hematocrit val-
ues of 5% were common just before death. Smears of
the peripheral blood showed visible evidence of ac-
quired abnormality in the structure of the erythrocytes
in the form of spherocytosis, poikilocytosis, and
anisocytosis (Figure 7). Fifteen to 21 days after in-
jection of Py-4-1 cells, numerous abnormal forms of
erythrocytes were observed in peripheral blood
smears including crenated erythrocytes and poikilo-
cytes (Figure 7, B and C). Blood smears stained for
reticulocytes revealed that the anemia was also char-
acterized by a marked reticulocytosis (Figure 7, D
and F). At the terminal stage, reticulocyte counts of
80% compared to 2.5% in controls were commonly
found (data not shown). Interestingly, white blood cell
counts remained normal during hemangioma devel-
opment (data not shown). Nine days after injection of
the Py-4-1 cells, the mice developed severe throm-
bocytopenia with a mean platelet count of 269,000
compared to 1,016,000 in controls of the same strain
(P< 0.001) (Figure 6D). Platelet counts decreased as
the size of the tumor increased and were as low as
44,000 in some mice at the terminal stage. These re-
sults are consistent with the diagnosis of heman-
gioma associated with hemolytic anemia and throm-
3-6,12bocytopenic purpura.
Bone Marrow Examination
Bone marrow sections and bone marrow smears were
examined to investigate the origin of the thrombocy-
topenia (Figure 8). Bone marrow examination from
tumor-bearing mice 21 days after injection revealed
an essentially normal marrow except for the presence
of numerous megakaryocytes (Figure 8, A and B). In
addition, bone marrow smear analysis showed the
presence of immature megakaryocytes characteristic
of thrombocytopenic purpura (Figure 8, C and
D).13-14 These results suggested that suppression of
the bone marrow was not a likely cause for the de-
crease in circulating platelets.
Discussion
The present study presents a murine model of he-
mangioma development. Py-4-1 endothelial cells in-
jected into histocompatible mice rapidly organized to
form vascular tumors at the site of injection with 100%
frequency. The histological and hematological fea-
tures of Py-4-1-derived vascular tumors during the
course of development were as follows. Immediately
after inoculation, Py-4-1 cells formed small aggre-
gates that soon organized into vascular spaces filled
with erythrocytes. Gradually, the spaces evolved into
DUu
Endothelial Cell Line-Derived Hemangioma 803



















a b c d e f
OX r - t _t0 D DN






a b c d e f
r- u
0 _- N
-6 X r- - 4 _-
_ I- b a _ c
c. :0 >% :1 21 :0
0 a a a a a

























a b c d e f a b c d e
Cl~I 0t- to
2_ , ,,, d ~~ ~~~N_ _ _ N
N c-
0a 0a 0 0o 0o 0c0
a lo 0
Figure 6. Time course ofRBC count (A), hemoglobin concentration (B), hematocrit (C), and platelet count (D) in tumor-bearing mice compared
to controls. Student's t test compared to control (A) b, P < 0.01; c, P < 0.05; d, P < 0.008; e, P < 0.001; f P < 0.001. (B) b, P < 0.02; c, P < 0.09;
d, P < 0.02; e, P < 0.0001;f P < 0.0001. (C) b, P < 0.1; c, P < 0.1; d, P < 0.02; e, P < 0.003;f P < 0.004. (D) b, P < 0.5; c, P < 0.001; d, P < 0.002;
e, P < 0.0001.
cystic cavities of different sizes. It is not clear whether
cystic cavity formation is due to the fusion between
adjacent spaces and/or to individual space expan-
sion. Simultaneous to cystic cavity formation, the
endothelial cells lining the vascular spaces prolifer-
ated extensively and organized into a multilayer lin-
ing. At the later stages, numerous large cystic cavities
were present and proliferating endothelial cells re-
mained to constitute the cyst walls. These cells, how-
ever, showed a poor organization with fewer intercel-
lular junctions. On the basis of these histological
features, the Py-4-1 tumors were previously catego-
rized as hemangioendotheliomas or simply as he-
mangiomas.15 As the hemangioma increased in size,
blood parameters including RBC count, hemoglobin
concentration, hematocrit and platelet count de-
creased significantly. This in turn lead to severe ane-
mia and thrombocytopenia that contributed to the
mortality of the mice. These hematological changes
are similar to those found in the Kasabach-Merritt
syndrome in human beings.3 6,14 The anemia in these
mice may have resulted from several factors such as
sequestration of the red blood cells in the tumor or
bleeding following rupture of the vascular channels
within the hemangioma. Several theories have been
proposed to explain the relationship between the he-
mangioma and the thrombocytopenia in the
Kasabach-Merritt syndrome including: 1) trapping or
utilization of platelets in the hemangioma, 2) in-
creased peripheral destruction of platelets, and 3)
decreased production of platelets in the bone mar-
row. In this mouse model, the major apparent cause
of thrombocytopenia is the trapping or utilization of
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Figure 7. Peripheral blood smnear (A to C) anld reticulocyte analysis (D to F) durin1g the tiune couirse of hemantgiona formation. Peripheral blood
smears ifmrnniice I day (A), 15 days (B), and 21 dai!s (C) aJier stuhcuitanieonus in/ectionn of Py-4-1 cells. Note the presetce of nnumerous crenated
erythrocytes or 'Buirr cells"(arrows in B) and sharp-anigled helmnet" cells orpoikilocytes (arrou's in C). Peripheral blood reticulocyte stainlingfrom
mnice I clay (D), 15 days (E), anid 21 days (F) after injectioni of P''-4-1 cells. NVote the increasing iiiinuber of clark staining reticulocytes. Scalc bar =
50 p.
lets sequestered within the hemangioma, the pres-
ence of numerous megakaryocytes in the bone mar-
row, and low plasma platelet counts provide the
primary evidence for this concept.
Objectives of therapy in the Kasabach-Merritt
syndrome are twofold: to control the coagulopathy
and to eradicate or reduce the size of the lesion. In
the past, selected patients had been treated with
corticosteroids or cytotoxic drugs, but these treat-
ments had adverse side effects and were inconsis-
tently effective.16-19 Some patients have benefited
from embolization of feeding vessels, surgical extir-
pation of the hemangioma, and anticoagulation
treatment.6'18'20-25 Radiation therapy is now rarely
employed for these patients as the incidence of
growth retardation and complications are significant.
Recombinant interferon is a relatively new addition to
the treatment of selected vascular malformations, and
the results in a few patients with aggressive heman-
giomas has been encouraging.26-29At this time, how-
Endothelial Cell Line-Derived Hemangioma 805
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Figure 8. Bone marrou study 21 days after subctutaneous injectioni oJ Py-4-1 cells. A: Bone marrow section (400X). B: Bonie marrow section
showinig the pre-sence of tnumerozus megakaryocytes (800X ). C and D: Bonie marrowi, smears revealing the presenice o] inmmature mnegakaryocytes
(C: 400X; D: 800X).
ever, the mechanisms of recombinant interferon ac-
tion in these patients are entirely unknown, as are the
appropriate dosage, interval, and duration. This mu-
rine model provides a good system to study the ef-
fects of recombinant interferon and other angiogen-
esis inhibitors on hemangioma formation and
endothelial cell proliferation.
In conclusion, Py-4-1 cells injected into histocom-
patible mice present a novel animal model to study
vascular tumors. This model is particularly convenient
to investigate vascular endothelial cell tumorigenesis
as well as to perform therapeutic studies because it
is easily manipulable, reproducible at 100% fre-
quency, and blood parameters can be followed to de-
termine if experimental treatment will influence tumor
progression. In addition, this model is suitable for ma-
nipulating Py-4-1 cells in vitro before inoculation. For
example, the cells could be transfected with a gene
construct encoding interferon-a. The effects of
interferon-a production by Py-4-1 cells on heman-
gioma formation and endothelial cell proliferation
could then be followed in vivo.
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